See All Slides - tctmd.com

Slides

Presentation TCT 2017

Predicting the Future: Will the Ongoing TAVR UNLOAD and Early TAVR Trials Change the Threshold for TAVR in Moderate and Asymptomatic Aortic Stenosis?

Presenter: David H. Adams, Ted Feldman, Allan Schwartz

October 30, 2017

Presentation TCT 2017

Perfusion-balloon Valvuloplasty Facilitating TAVR Without Rapid Pacing: The TRUE-FLOW Study

Presenter: Nicolo Piazza, Josep Rodés-Cabau, Felix Woitek

October 30, 2017

Presentation TCT 2017

Case #4: Unbelievable PCI CTO Complication

Presenter: Teguh Santoso, Yoshito Yamamoto, Wen-Lieng Lee

October 30, 2017

Presentation TCT 2017

Is Ventricular Arrhythmia After Ablation a Real Phenomenon?

Presenter: Srihari S. Naidu, Paul Sorajja, George S. Hanzel

October 30, 2017

Presentation TCT 2017

Anticoagulation Following DVT/PE Intervention: What, When, Why, and for How Long?

Presenter: Michael R. Jaff, Robert A. Lookstein, Teresa L. Carman

October 30, 2017

Presentation TCT 2017

Human Cell Derived Off-The-Shelf Tissue Engineered Heart Valves for Next Generation TAVR: A Proof-of-Concept Study in Adult Sheep

Presenter: Nicolo Piazza, Josep Rodés-Cabau, Valentina Lintas

October 30, 2017

Presentation TCT 2017

Bioresorbable Scaffolds in a Coronary CTO

Presenter: Teguh Santoso, Yoshito Yamamoto

October 30, 2017

Presentation TCT 2017

First-in-Man Experience With a Large Bore (?14 FR) Bio-Resorbable Vascular Closure Device

Presenter: Nicolo Piazza, Josep Rodés-Cabau, Ronald Caputo

October 30, 2017

Presentation TCT 2017

Novel Technique: Use of Mother in Child Guideliner Catheter as a Conduit for Optimal Visualization and Deployment of Stents in Coronary Ostial Lesions

Presenter: Peter L Duffy, Yuejin Yang, Harinder K Bali

October 30, 2017

Presentation TCT 2017

Predicting the Future: Will the Ongoing GALILEO and ENVISAGE AF Trials Change How We Anticoagulate Patients After TAVR?

Presenter: David H. Adams, Ted Feldman, Vinod H. Thourani

October 30, 2017

Advertisement

Slides

Predicting the Future: Will the Ongoing TAVR UNLOAD and Early TAVR Trials Change the Threshold for TAVR in Moderate and Asymptomatic Aortic Stenosis?

Perfusion-balloon Valvuloplasty Facilitating TAVR Without Rapid Pacing: The TRUE-FLOW Study

Case #4: Unbelievable PCI CTO Complication

Is Ventricular Arrhythmia After Ablation a Real Phenomenon?

Anticoagulation Following DVT/PE Intervention: What, When, Why, and for How Long?

Human Cell Derived Off-The-Shelf Tissue Engineered Heart Valves for Next Generation TAVR: A Proof-of-Concept Study in Adult Sheep

Bioresorbable Scaffolds in a Coronary CTO

First-in-Man Experience With a Large Bore (?14 FR) Bio-Resorbable Vascular Closure Device

Novel Technique: Use of Mother in Child Guideliner Catheter as a Conduit for Optimal Visualization and Deployment of Stents in Coronary Ostial Lesions

Predicting the Future: Will the Ongoing GALILEO and ENVISAGE AF Trials Change How We Anticoagulate Patients After TAVR?

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content